Trial Profile
A 16-week, Single Arm, Multicenter Study for the Assessment of Efficacy and Safety of Secukinumab in aduLt Patients With Moderate to Severe plaquE Psoriasis in Turkish Population
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2019
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 19 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Jun 2016 New trial record